KIRKLAND, QC, March 6, 2019 /CNW Telbec/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) ("Ortho RTi" or the "Corporation"), an emerging Orthopaedic and Sports Medicine Technology company, today announced the appointment of Mr. Steve Saviuk as Chairman of the Board of Directors. Dr. Brent Norton, who previously held this position, remains on the Board of Directors and continues to lead the Corporation as its President and Chief Executive Officer. The Corporation also announced that Ms. Sharon M. Ludlow has resigned today from the Board of Directors.
"I look forward to taking this role and allowing Brent to focus on operational and strategic issues going forward." said Steve Saviuk, the new Chairman of the Board of Directors of the Corporation. "Also, on behalf of the Board and staff of Ortho RTi, I would like to take this opportunity to thank Sharon for her contribution and support to the Corporation during her tenure as Director."
About Ortho Regenerative Technologies Inc.
Ortho RTi is an emerging Orthopaedic and Sports Medicine biologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to tendons, meniscus, ligaments and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant bioactivity and residency of our proprietary biopolymer, Ortho RTi continues to assess its potential for therapeutic uses outside of the soft tissue repair. Further information about Ortho RTi is available on the Company's website at www.orthorti.com and on SEDAR at www.sedar.com.
This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE Ortho Regenerative Technologies Inc.
For further information: Brent Norton MD, MBA, ICD.D, Chief Executive Officer, 514.782.0951, firstname.lastname@example.org